Monitoring cancer prognosis, diagnosis and treatment efficacy using metabolomics and lipidomics

Emily G. Armitage, Andrew D. Southam

Research output: Contribution to journalArticlepeer-review

54 Citations (Scopus)
130 Downloads (Pure)

Abstract

Introduction

Cellular metabolism is altered during cancer initiation and progression, which allows cancer cells to increase anabolic synthesis, avoid apoptosis and adapt to low nutrient and oxygen availability. The metabolic nature of cancer enables patient cancer status to be monitored by metabolomics and lipidomics. Additionally, monitoring metabolic status of patients or biological models can be used to greater understand the action of anticancer therapeutics.

Objectives

Discuss how metabolomics and lipidomics can be used to (i) identify metabolic biomarkers of cancer and (ii) understand the mechanism-of-action of anticancer therapies. Discuss considerations that can maximize the clinical value of metabolic cancer biomarkers including case–control, prognostic and longitudinal study designs.

Methods

A literature search of the current relevant primary research was performed.

Results

Metabolomics and lipidomics can identify metabolic signatures that associate with cancer diagnosis, prognosis and disease progression. Discriminatory metabolites were most commonly linked to lipid or energy metabolism. Case–control studies outnumbered prognostic and longitudinal approaches. Prognostic studies were able to correlate metabolic features with future cancer risk, whereas longitudinal studies were most effective for studying cancer progression. Metabolomics and lipidomics can help to understand the mechanism-of-action of anticancer therapeutics and mechanisms of drug resistance.

Conclusion

Metabolomics and lipidomics can be used to identify biomarkers associated with cancer and to better understand anticancer therapies.
Original languageEnglish
JournalMetabolomics
Volume12
Issue number9
Early online date16 Aug 2016
DOIs
Publication statusPublished - 1 Sep 2016

Fingerprint

Dive into the research topics of 'Monitoring cancer prognosis, diagnosis and treatment efficacy using metabolomics and lipidomics'. Together they form a unique fingerprint.

Cite this